The risk-benefit analysis used by the U.S. Food and Drug Administration (FDA) to grant emergency use authorization (EUA) to Pfizer’s Wuhan coronavirus (Covid-19) “vaccine” for children aged 5 to 11 is “critically flawed,” warns Children’s Health Defense (CHD). The FDA failed to take into account natural immunity, for instance, which U.S. Centers for Disease Control and Prevention … Continue reading FDA used “critically flawed” risk-benefit analysis to approve covid “vaccines” for children
Dr. Eddy Bettermann MD 